Phase 3 Nephropathy Clinical Trials
21 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Biogen180 enrolled91 locationsNCT06962800
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 3
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Phase 3
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
Primary Membranous Nephropathy
Huashan Hospital144 enrolled1 locationNCT06781944
Recruiting
Phase 2Phase 3
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Membranous Nephropathy - PLA2R Induced
Radboud University Medical Center20 enrolled1 locationNCT07163611
Recruiting
Phase 2Phase 3
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
Heart FailureAcute Kidney InjuryPercutaneous Coronary Intervention+2 more
VA Office of Research and Development240 enrolled3 locationsNCT04982419
Recruiting
Phase 3
Different Immunosuppressive Treatment in iMN
Idiopathic Membranous Nephropathy
Peking Union Medical College Hospital200 enrolled1 locationNCT04745728
Recruiting
Phase 3
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Membranous Nephropathy
Centre Hospitalier Universitaire de Nice120 enrolled13 locationsNCT06341205
Recruiting
Phase 3
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd.378 enrolled1 locationNCT07014826
Recruiting
Phase 2Phase 3
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd216 enrolled21 locationsNCT06470191
Recruiting
Phase 3
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.360 enrolled1 locationNCT06819826
Recruiting
Phase 3
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Primary Membranous Nephropathy
Cerium Pharmaceuticals, Inc.148 enrolled31 locationsNCT05696613
Not Yet Recruiting
Phase 3
A study of the effect and safety of sparsentan in the treatment of patients with immunoglobulin A nephropathy.
Immunoglobulin A Nephropathy
Retrophin, Inc.280 enrolled25 locationsACTRN12618001511224
Not Yet Recruiting
Phase 3
FAN Trial: A randomised-controlled trial assessing the effect of lisinopril on Fontan-Associated Nephropathy
Nephropathy
Murdoch Children's Research Institute80 enrolled3 locationsACTRN12618001124224